ABOUT SIEGFRIED
Siegfried is a leading contract development and manufacturing organization with a global network of 16 production sites in the US, Europe, China and Australia. With more than 150 years of experience, we are taking your innovations to industrial scale.
We offer CDMO services for small, midsize, and large pharmaceutical companies from preclinical to commercial, accelerating their time to market while ensuring quality and reliability.
INDUSTRY INSIGHTS
-
How can manufacturers balance security, compliance, and supply continuity in controlled substance development and production?
-
Reduce development risk and improve readiness for larger trials with strategies that align formulation, manufacturing, and commercialization goals.
-
Could decisions made today impact your regulatory timeline years from now? Explore the value of early planning and regional expertise.
-
The right formulation strategy can accelerate clinical timelines and set the stage for successful later-phase development.
-
Integrated manufacturing strategies, flexible CMC capabilities, AI-driven technologies, and connected data ecosystems are helping organizations reduce delays and improve efficiency from development through commercialization.
-
Clinical momentum starts before the clinic. Formulation, manufacturing, and dosage form strategies can shape a program's future trajectory.
-
What really accelerates drug development? Increasingly, it's the combination of AI, Quality by Design, and data-driven decision-making.
-
Derivatization can improve detection, separation, and quantification, providing a practical solution for challenging analyses while supporting reliable quality control and regulatory compliance.
-
Dry powder inhalers offer major delivery advantages, but realizing their potential requires expertise across development, analytics, and production.
-
The most efficient inventory may be the inventory you haven't labeled yet. See how white label stocking creates greater flexibility across markets.
-
Domestic development strategies can help reduce delays, improve communication, and support more efficient progress toward clinical milestones.
-
Spray drying helps overcome formulation challenges by improving solubility, bioavailability, and particle performance for complex drug candidates.
-
Successful drug development requires more than a one-size-fits-all approach. Explore strategies tailored to each stage of the journey.
-
As development demands grow, success depends on flexibility and resilience. Learn how manufacturers are adapting to meet new challenges.
-
The right early-stage strategy can prevent costly delays later. Explore key considerations for advancing programs to the clinic with confidence.
-
How can manufacturers improve process control and flexibility? Explore the benefits of combining QbD with mechanistic modeling.
-
Accelerating clinical timelines starts with a strong foundation. Discover how smart development strategies can reduce risk, conserve resources, and support future scale-up.
-
Pharmaceutical innovation depends on speed and smarter decisions. Discover how advanced R&D technologies and real-time insights are helping accelerate development.
-
From scalable manufacturing to supply chain resilience, discover the strategies helping developers navigate complexity and bring therapies to market faster.
-
From package design to advanced testing technologies, discover the critical elements of maintaining sterility and preserving product quality over time.
CONTACT INFORMATION
Siegfried
Untere Brühlstrasse 4
Zofingen, 4800
SWITZERLAND
SOLUTIONS
-
The Acceleration Hub provides small-scale GMP manufacturing for specialized and low-volume APIs. High-containment infrastructure, flexible equipment, and dedicated process design support reliable production and efficient progression into commercial supply.
-
At Acceleration Hub, we work with emerging biotech companies and large pharma partners, combining route selection, process development, analytical capabilities, and manufacturing into one coordinated approach - including expertise in highly potent APIs and controlled substances.
With experienced teams, established processes, and dedicated infrastructure, we enable efficient project progression under tight timelines and evolving requirements.
-
At Siegfried, we combine scientific expertise with a global manufacturing network to deliver reliable, high-quality custom APIs for innovative medicines, from early development to commercial scale.
-
From early-phase development to commercial manufacturing and packaging, we provide integrated solutions for the most complex Oral Solid Dosage (OSD) products. Our experienced teams combine deep technical expertise and advanced manufacturing capabilities to help accelerate development and ensure reliable product supply throughout the entire product life cycle.
-
From established controlled substances to pharmaceutical-grade caffeine, Siegfried provides a comprehensive portfolio of high-quality pharma APIs to customers in over 70 countries worldwide. Combining decades of scientific expertise with global manufacturing capabilities and deep regulatory knowledge, we support pharmaceutical companies with secure, reliable supply of generic APIs across a broad range of therapeutic areas, including anesthetics, analgesics, decongestants and addiction treatment.
-
Your expert partner for end-to-end sterile and aseptic fill-finish solutions for prefilled syringes, cartridges and vials - from clinical stage projects to commercial supply.
-
Siegfried is your expert in ophthalmic formulations with outstanding manufacturing and packaging capabilities.
-
Siegfried is an expert in manufacturing capsule-based dry powder inhalation products.
NEWS
- Siegfried Delivers Profitable Growth And Confirms Outlook
- Siegfried Strengthens Manufacturing Network With New Large-Scale Drug Substance Facility In Minden
- Siegfried Successfully Places Senior Bonds Of CHF 200 Million
- Siegfried Included In Dow Jones Best-In-Class Europe Index
- Siegfried DINAMIQS Receives Swissmedic License For Viral Vector Manufacturing
- Siegfried Obtains Antitrust Clearance For Acquisition Of Three Drug Substances Sites In The US And Australia
- Siegfried Shareholders Approve All Proposals At Annual General Meeting 2026
- Siegfried Delivers Strong Profitability And Continued Growth
- Siegfried To Acquire High-Quality Small Molecules Drug Substance Capacity In The US